1941 Results
Sort By:
Published on July 17, 2014
A San Diego startup whose technology promises to enable the clinical use of genomics by radically reducing the cost and time of analyzing next-generation sequencing (NGS) data is attractive enough to have drawn Gregory Lucier among investors that have joined to raise $10 million in Series A financing. Lucier has…
Published on July 16, 2014
As you have probably noticed, there’s been a major shift in the focus of next-gen sequencing over the past couple of years. First it was all about new genomes, new techniques, and discovery. Now it’s all about translation. We are entering a new era in next-gen sequencing, one in which…
Published on July 7, 2014
Sequence-based clinical diagnostics firm and deCODE genetics spinout NextCODE Health is partnering with the Academic Centre on Rare Diseases (ACoRD) at University College Dublin, allowing ACoRD to use NextCODE products in research aimed at learning more about the causes and better ways to diagnose autism and rare diseases. NextCODE's Clinical…
Published on June 30, 2014
Illumina entered three separate deals with three European labs under which they will use Illumina's consumables and the HiSeq 2500 to develop and perform noninvasive prenatal testing (NIPT) in their respective nations. French lab-testing service firm Biomnis will make NIPT available in France, Italian molecular genetics lab Genoma will perform…
Published on June 26, 2014
Recent developments reveal both the beginnings of consensus, and many more unresolved issues, when it comes to “incidental” or unexpected findings uncovered during genome or exome sequencing. The American College of Medical Genetics and Genomics (ACMG) retreated in April from its controversial recommendation last year that labs should return incidental…
Published on June 26, 2014
As recently as ten years ago, just after completion of the Human Genome Project, the concept of a personalized approach to cancer treatment was largely just that—an idea of what could be. And companion diagnostics were limited to predicting patient response to Herceptin for breast cancer and Gleevec for chronic…
Published on June 25, 2014
Personalized medicine is gaining momentum, but it needs yet more impetus to break into the healthcare mainstream, argues a new report. Released on June 25 by the Personalized Medicine Coalition (PMC), the report examines opportunities for the continued development and adoption of personalized medicine as the cost of genetic sequencing…
Published on June 12, 2014
Technological advances such as high-throughput sequencing are transforming medicine from symptom-based diagnosis and treatment to personalized medicine as scientists employ novel rapid genomic methodologies to gain a broader comprehension of disease and disease progression. As next-generation sequencing becomes more rapid, researchers are turning toward large-scale pan-omics, the collective use of…
Published on June 10, 2014
This report represents qualitative and quantitative metrics of the next-generation sequencing (NGS) landscape and frames it into the context of various biomarker classes. Highlights of this report: The NGS field is expanding and its quantitative penetrance into clinical testing is growing. We present in this report some data illustrating the…
Published on May 28, 2014
The history of science is replete with instances of multiple discovery—the more or less simultaneous announcement of essentially the same breakthrough by independent researchers. Still, it may still seem uncanny that two separate research groups not only produced a draft map of the human proteome, they also published their results…
Published on May 20, 2014
With a little help from Sloan Kettering Institute chair Marie-Josée Kravis and her husband, philanthropist Henry R. Kravis, the Memorial Sloan Kettering Cancer Center (MSK) is launching a new program that it says will reshape clinical trials and speed up translation of molecular discoveries into routine clinical practice. Dubbed the…
Published on May 16, 2014
The use of targeted agents against key signaling kinases is transforming cancer treatment. Drugs such as Herceptin and Zelboraf have increased progression-free survival in breast cancer and melanoma respectively and are far from the only examples. However, the complexity of signaling pathway networks allows tumor cells to adapt under monotherapy…
Published on May 16, 2014
N-of-One inked an agreement with Belgian personalized medicine firm OncoDNA under which it will provide clinical interpretation for all of OncoDNA's next-generation sequencing (NGS) and other molecular tests for patients throughout Europe, the Middle East, and other parts of the world. OncoDNA provides tumor profiling services designed to help medical…
Published on May 15, 2014
Next-generation sequencing (NGS) has been making tremendous strides in the research market and with Illumina’s recent launch of the HiSeq X Ten, we’ve essentially reached the $1,000 genome (notwithstanding quibbles over what exactly should be accounted for in the $1,000). With these advancements, the pull to adapt NGS for the…
Published on May 15, 2014
While the first traffic light flashed 18 years before the first car was built, the rules of the road have long lagged behind technology where genetic testing is concerned, especially in distinguishing functional gene variants from those that cause disease. That is starting to change as groups of researchers and…